Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months

You may also be interested in...



Australia Ramps Up Early Research Via Medical Research Commercialization Fund

Funding for early-stage research has been a huge problem in Australia until recently, and new funding mechanisms have come just in time as research begun a decade ago moves into development.

Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund

PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20

Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund

PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel